Leerink Partnrs Has Negative Outlook of AxoGen Q4 Earnings

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Investment analysts at Leerink Partnrs decreased their Q4 2025 earnings estimates for AxoGen in a research note issued to investors on Monday, July 14th. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings per share of $0.01 for the quarter, down from their prior estimate of $0.02. The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group reduced their target price on shares of AxoGen from $26.00 to $24.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, AxoGen presently has a consensus rating of "Buy" and an average target price of $24.50.

AxoGen Price Performance

NASDAQ:AXGN traded up $0.15 during trading hours on Wednesday, reaching $11.82. 620,922 shares of the company's stock were exchanged, compared to its average volume of 512,871. The company has a market capitalization of $538.28 million, a P/E ratio of -78.79 and a beta of 1.04. AxoGen has a 12 month low of $7.34 and a 12 month high of $21.00. The company has a quick ratio of 2.65, a current ratio of 4.28 and a debt-to-equity ratio of 0.63. The business's 50-day simple moving average is $11.03 and its two-hundred day simple moving average is $15.21.

Hedge Funds Weigh In On AxoGen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. boosted its stake in shares of AxoGen by 2.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,023,122 shares of the medical equipment provider's stock valued at $11,101,000 after buying an additional 21,905 shares during the period. Exchange Traded Concepts LLC boosted its stake in shares of AxoGen by 50.9% during the 2nd quarter. Exchange Traded Concepts LLC now owns 77,312 shares of the medical equipment provider's stock valued at $839,000 after buying an additional 26,077 shares during the period. Rhumbline Advisers boosted its stake in shares of AxoGen by 3.5% during the 1st quarter. Rhumbline Advisers now owns 60,264 shares of the medical equipment provider's stock valued at $1,115,000 after buying an additional 2,032 shares during the period. Acadian Asset Management LLC boosted its stake in shares of AxoGen by 41.0% during the 1st quarter. Acadian Asset Management LLC now owns 226,812 shares of the medical equipment provider's stock valued at $4,194,000 after buying an additional 65,929 shares during the period. Finally, Jones Financial Companies Lllp boosted its stake in shares of AxoGen by 104,810.0% during the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider's stock valued at $194,000 after buying an additional 10,481 shares during the period. Institutional investors and hedge funds own 80.29% of the company's stock.

Insider Buying and Selling

In related news, Director Joseph A. Tyndall sold 20,062 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $11.20, for a total value of $224,694.40. Following the completion of the transaction, the director owned 15,345 shares of the company's stock, valued at approximately $171,864. This trade represents a 56.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.78% of the company's stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.